Increased CSF biomarkers of angiogenesis in Parkinson disease

Objective: To study biomarkers of angiogenesis in Parkinson disease (PD), and how these are associated with clinical characteristics, blood–brain barrier (BBB) permeability, and cerebrovascular disease. Methods: In this cross-sectional analysis, 38 elderly controls and 100 patients with PD (82 without dementia and 18 with dementia) were included from the prospective Swedish BioFinder study. CSF samples were analyzed for the angiogenesis biomarkers vascular endothelial growth factor (VEGF); its receptors, VEGFR-1 and VEGFR-2; placental growth factor (PlGF); angiopoietin 2 (Ang2); and interleukin-8. BBB permeability, white matter lesions (WMLs), and cerebral microbleeds (CMB) were assessed. CSF angiogenesis biomarkers were also measured in 2 validation cohorts: (1) 64 controls and 87 patients with PD with dementia; and (2) 35 controls and 93 patients with neuropathologically confirmed diagnosis of PD with and without dementia. Results: Patients with PD without dementia displayed higher CSF levels of VEGF, PlGF, and sVEGFR-2, and lower levels of Ang2, compared to controls. Similar alterations in VEGF, PlGF, and Ang2 levels were observed in patients with PD with dementia. Angiogenesis markers were associated with gait difficulties and orthostatic hypotension as well as with more pronounced BBB permeability, WMLs, and CMB. Moreover, higher levels of VEGF and PlGF levels were associated with increased CSF levels of neurofilament light (a marker of neurodegeneration) and monocyte chemotactic protein–1 (a marker of glial activation). The main results were validated in the 2 additional cohorts. Conclusions: CSF biomarkers of angiogenesis are increased in PD, and they are associated with gait difficulties, BBB dysfunction, WMLs, and CMB. Abnormal angiogenesis may be important in PD pathogenesis and contribute to dopa-resistant symptoms.

[1]  M. Silvestrini,et al.  Increased CSF biomarkers of angiogenesis in Parkinson disease , 2016, Neurology.

[2]  R. Dobbs,et al.  Peripheral aetiopathogenic drivers and mediators of Parkinson’s disease and co-morbidities: role of gastrointestinal microbiota , 2015, Journal of NeuroVirology.

[3]  J. Woulfe,et al.  Striatal Blood–Brain Barrier Permeability in Parkinson'S Disease , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  I. Biaggioni.  New Developments in the Management of Neurogenic Orthostatic Hypotension , 2014, Current Cardiology Reports.

[5]  K. Blennow,et al.  Blood–cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment , 2014, Psychiatry Research.

[6]  D. Munoz,et al.  Alpha‐synuclein in the appendiceal mucosa of neurologically intact subjects , 2014, Movement disorders : official journal of the Movement Disorder Society.

[7]  D. Munoz,et al.  Hypothesis: a role for EBV-induced molecular mimicry in Parkinson's disease. , 2014, Parkinsonism & related disorders.

[8]  L. Minthon,et al.  Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study , 2014, BMC Neurology.

[9]  S. Tsirka,et al.  Monocyte chemoattractant protein-1 and the blood–brain barrier , 2014, Cellular and Molecular Life Sciences.

[10]  T. Byzova,et al.  Oxidative stress in angiogenesis and vascular disease. , 2014, Blood.

[11]  Patricia M. Desmond,et al.  Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations , 2013, Front. Neurol..

[12]  Kwang-Soo Lee,et al.  Orthostatic and Supine Blood Pressures Are Associated with White Matter Hyperintensities in Parkinson Disease , 2013, Journal of the Neurological Sciences.

[13]  Sara Hall,et al.  Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment , 2013, Brain, Behavior, and Immunity.

[14]  K. Blennow,et al.  Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples , 2013, Alzheimer's Research & Therapy.

[15]  J. Li,et al.  TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1 , 2013, Proceedings of the National Academy of Sciences.

[16]  M. Ferrari,et al.  Syncope and orthostatic intolerance increase risk of brain lesions in migraineurs and controls , 2013, Neurology.

[17]  E. Mackenzie,et al.  Angiopoietin-2 is Vasoprotective in the Acute Phase of Cerebral Ischemia , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  K. Blennow,et al.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.

[19]  D. Werring,et al.  Association of cerebral microbleeds in acute ischemic stroke with high serum levels of vascular endothelial growth factor. , 2012, Archives of neurology.

[20]  A. Pisani,et al.  Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease , 2012, Journal of Neuroinflammation.

[21]  Jeremy Seto,et al.  Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. , 2012, The Journal of clinical investigation.

[22]  Oskar Hansson,et al.  CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease , 2012, PloS one.

[23]  Fair M. Vassoler,et al.  Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. , 2011, Brain : a journal of neurology.

[24]  Arndt F. Siekmann,et al.  The role of chemokines and their receptors in angiogenesis , 2011, Cellular and Molecular Life Sciences.

[25]  Nicolaas I. Bohnen,et al.  White matter lesions in Parkinson disease , 2011, Nature Reviews Neurology.

[26]  R. Mayeux,et al.  Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.

[27]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[28]  B. Zlokovic.  The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[29]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[30]  J. Cano,et al.  Blood–brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons , 2007, Journal of neurochemistry.

[31]  B. Mermillod,et al.  Is cerebral autoregulation impaired in Parkinson's disease? A transcranial Doppler study , 2007, Journal of the Neurological Sciences.

[32]  H. Augustin,et al.  Angiopoietins: a link between angiogenesis and inflammation. , 2006, Trends in immunology.

[33]  C. Brosnan,et al.  IL-1β Regulates Blood-Brain Barrier Permeability via Reactivation of the Hypoxia-Angiogenesis Program1 , 2006, The Journal of Immunology.

[34]  Y. Mizuno,et al.  Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease , 2006, Neuroreport.

[35]  J. Martin Collinson,et al.  Corneal avascularity is due to soluble VEGF receptor-1 , 2006, Nature.

[36]  D. Cheresh,et al.  Pathophysiological consequences of VEGF-induced vascular permeability , 2005, Nature.

[37]  J. Weis,et al.  Interleukin‐6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1 , 2005, International journal of cancer.

[38]  J. Bart,et al.  Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.

[39]  E. Hirsch,et al.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian , 2005, Journal of Neural Transmission.

[40]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[41]  H. Chui,et al.  Subcortical ischaemic vascular dementia , 2002, The Lancet Neurology.

[42]  E. Hirsch,et al.  Blood vessels change in the mesencephalon of patients with Parkinson's disease , 1999, The Lancet.

[43]  J. Foucher,et al.  Risperidone-induced tardive dystonia and psychosis , 1999, The Lancet.

[44]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[45]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. Minthon,et al.  CCL 2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer ’ s Disease , 2012 .

[47]  Julie A. Schneider,et al.  Evidence for angiogenesis in Parkinson’s disease, incidental Lewy body disease, and progressive supranuclear palsy , 2011, Journal of Neural Transmission.

[48]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[49]  P. Novak,et al.  Autoregulation of cerebral blood flow in orthostatic hypotension. , 1998, Stroke.